# A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Type 2 Diabetes Mellitus Subjects (T2DM) Treated With Basal + Prandial Insulin

> **NCT06767761** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Gan & Lee Pharmaceuticals.** · enrollment: 580 (estimated)

## Conditions studied

- Diabetes

## Interventions

- **DRUG:** GZR4
- **DRUG:** Insulin Glargine U100 group

## Key facts

- **NCT ID:** NCT06767761
- **Lead sponsor:** Gan & Lee Pharmaceuticals.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-02-18
- **Primary completion:** 2026-03-19
- **Final completion:** 2026-04-09
- **Target enrollment:** 580 (ESTIMATED)
- **Last updated:** 2025-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06767761

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06767761, "A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Type 2 Diabetes Mellitus Subjects (T2DM) Treated With Basal + Prandial Insulin". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06767761. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*